Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: A EULAR initiative

Annals of the Rheumatic Diseases

Volumn 75, Issue 6, 2016, Pages 965-973

  Baillet, Athan ^a   Gossec, Laure ^b   Carmona, Loreto ^c   De Wit, Maarten ^d   Van Eijk Hustings, Yvonne ^e   Bertheussen, Heidi ^d   Alison, Kent ^f   Toft, Mette ^d   Kouloumas, Marios ^g   Ferreira, Ricardo J O ^h   Oliver, Susan ⁱ   Rubbert Roth, Andrea ^j   Van Assen, Sander ^k   Dixon, William G ^l   Finckh, Axel ^m   Zink, Angela ⁿ   Kremer, Joel ^o   Kvien, Tore K ^p   Nurmohamed, Michael ^q   Van Der Heijde, Desirée ^r   Dougados, Maxime ^s   more..

^a UNIV GRENOBLE ALPES   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c Instituto de Salud   (Spain)

^d EULAR Standing Committee of People with Arthritis/Rheumatism in Europe (PARE)   (Switzerland)

^e MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^f SALISBURY DISTRICT HOSPITAL   (United Kingdom)

^g Cyprus League against Rheumatism   (Cyprus)

^h CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

ⁱ Independent Nurse Consultant   (United Kingdom)

^j UNIVERSITY OF COLOGNE   (Germany)

^k UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^l UNIVERSITY OF MANCHESTER   (United Kingdom)

^m GENEVA UNIVERSITY HOSPITALS   (Switzerland)

ⁿ CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^o Center for Rheumatology LLP   (United States)

^p DIAKONHJEMMET HOSPITAL   (Norway)

^q VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^r LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^s PRES Sorbonne Paris Cité ^*  (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; DIPHTHERIA VACCINE; HEPARIN; HEPATITIS B VACCINE; INFLUENZA VACCINE; INSULIN; NONSTEROID ANTIINFLAMMATORY AGENT; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; TETANUS TOXOID; VARICELLA ZOSTER VACCINE; WART VIRUS VACCINE;

ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC INFLAMMATION; CLINICAL PRACTICE; COMORBIDITY; CONSENSUS; DEPRESSION; DIABETES MELLITUS; DIPHTHERIA; EVIDENCE BASED MEDICINE; GASTROINTESTINAL DISEASE; HEALTH PRACTITIONER; HEPATITIS B; HERPES ZOSTER; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INFECTION; INFLUENZA; ISCHEMIA; MALIGNANT NEOPLASTIC DISEASE; MAMMOGRAPHY; MEDICAL EXPERT; MEDICAL SOCIETY; OSTEOPOROSIS; PAPILLOMAVIRUS INFECTION; PNEUMOCOCCAL INFECTION; POLIOMYELITIS; POPULATION RESEARCH; PRIORITY JOURNAL; RHEUMATIC DISEASE; RHEUMATOLOGY; RISK FACTOR; SCORING SYSTEM; SMOKING; STANDARDIZATION; SYSTEMATIC REVIEW; TETANUS; VACCINATION; COMPLICATION; GASTROINTESTINAL DISEASES; NEOPLASMS; PROCEDURES; RISK ASSESSMENT;

COMORBIDITY; CONSENSUS; DEPRESSION; EVIDENCE-BASED MEDICINE; GASTROINTESTINAL DISEASES; HUMANS; ISCHEMIA; NEOPLASMS; OSTEOPOROSIS; RHEUMATIC DISEASES; RISK ASSESSMENT; RISK FACTORS;

EID: 84962238999     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2016-209233     Document Type: Article

References (77)

1. Maradit-Kremers H, Crowson CS, Nicola PJ, et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 2005;52:402-11.
2. Hickson LJ, Crowson CS, Gabriel SE, et al. Development of reduced kidney function in rheumatoid arthritis. Am J Kidney Dis 2014;63:206-13.
3. Giles JT, Danoff SK, Sokolove J, et al. Association of fine specificity and repertoire expansion of anticitrullinated peptide antibodies with rheumatoid arthritis associated interstitial lung disease. Ann Rheum Dis 2014;73:1487-94.
4. Van Assen S, Agmon-Levin N, Elkayam O, et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2011;70:414-22.
5. Dougados M, Soubrier M, Antunez A, et al. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis 2014;73:62-8.
6. Eichenauer DA, Engert A, Dreyling M, et al. Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011;22 (Suppl 6):vi55-8.
7. Baillet A, Payraud E, Niderprim V-A, et al. A dynamic exercise programme to improve patients' disability in rheumatoid arthritis: a prospective randomized controlled trial. Rheumatology (Oxford) 2009;48:410-15.
8. Bremander A, Petersson IF, Bergman S, et al. Population-based estimates of common comorbidities and cardiovascular disease in ankylosing spondylitis. Arthritis Care Res (Hoboken) 2011;63:550-6.
9. Lanza FL, Chan FK, Quigley EM, et al. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 2009;104:728-38.
10. Matcham F, Rayner L, Steer S, et al. The prevalence of depression in rheumatoid arthritis: a systematic review and meta-analysis. Rheumatology (Oxford) 2013;52:2136-48.
11. Peters MJ, Symmons DP, McCarey D, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010;69:325-31.
12. Nurmohamed MT, Heslinga M, Kitas GD. Cardiovascular comorbidity in rheumatic diseases. Nat Rev Rheumatol 2015;11:693-704.
13. Kanis JA, Burlet N, Cooper C, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2008;19:399-428.
14. Dougados M, Soubrier M, Perrodeau E, et al. Impact of a nurse-led programme on comorbidity management and impact of a patient self-assessment of disease activity on the management of rheumatoid arthritis: results of a prospective, multicentre, randomised, controlled trial (COMEDRA). Ann Rheum Dis 2015;74:1725-33.
15. Solomon DH, Curhan GC, Rimm EB, et al. Cardiovascular risk factors in women with and without rheumatoid arthritis. Arthritis Rheum 2004;50:3444-9.
16. MacLean CH, Louie R, Leake B, et al. Quality of care for patients with rheumatoid arthritis. JAMA 2000;284:984-92.
17. Curtis JR, Arora T, Narongroeknawin P, et al. The delivery of evidence-based preventive care for older Americans with arthritis. Arthritis Res Ther 2010; 12:R144.
18. Kremers HM, Bidaut-Russell M, Scott CG, et al. Preventive medical services among patients with rheumatoid arthritis. J Rheumatol 2003;30:1940-7.
19. Stavropoulos-Kalinoglou A, Metsios GS, Panoulas VF, et al. Underweight and obese states both associate with worse disease activity and physical function in patients with established rheumatoid arthritis. Clin Rheumatol 2009;28:439-44.
20. Gossec L, Salejan F, Nataf H, et al. Challenges of cardiovascular risk assessment in the routine rheumatology outpatient setting: an observational study of 110 rheumatoid arthritis patients. Arthritis Care Res (Hoboken) 2013;65:712-17.
21. Dougados M, Nataf H, Steinberg G, et al. Relative importance of doctor-reported outcomes vs patient-reported outcomes in DMARD intensification for rheumatoid arthritis: the DUO study. Rheumatology (Oxford) 2013;52:391-9.
22. van Eijk-Hustings Y, van Tubergen A, Boström C, et al. EULAR recommendations for the role of the nurse in the management of chronic inflammatory arthritis. Ann Rheum Dis 2012;71:13-19.
23. Loza E, Lajas C, Andreu JL, et al. Consensus statement on a framework for the management of comorbidity and extra-articular manifestations in rheumatoid arthritis. Rheumatol Int 2015;35:445-58.
24. van der Heijde D, Aletaha D, Carmona L, et al. 2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations. Ann Rheum Dis 2015;74:8-13.
25. Horwich A, Parker C, de Reijke T, et al. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24(Suppl 6):vi106-14.
26. Braillon A, Dubois G. [PSA (prostate specific antigen): Haute Autorite de Santé, American Cancer Society and National Health Service. Discrepancy between concepts for assessment]. Presse Med 2011;40:112-14.
27. Howick J, Chalmers I, Glasziou P, et al. Explanation of the 2011 Oxford Centre for Evidence-Based Medicine (OCEBM) Levels of Evidence. Oxford Centre for Evidence-Based Medicine. http://www.cebm.net/index.aspx?o=5653
28. Sellam J, Berenbaum F. The role of synovitis in pathophysiology and clinical symptoms of osteoarthritis. Nat Rev Rheumatol 2010;6:625-35.
29. Mosca M, Tani C, Aringer M, et al. European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis 2010;69:1269-74.
30. Duru N, van der Goes MC, Jacobs JW, et al. EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2013;72:1905-13.
31. Nurmohamed MT. EULAR Recommendations update on cardiovascular disease in RA[abstract]. Ann Rheum Dis 2015;74(Suppl 9).
32. Conroy RM, Pyorala K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003;24:987-1003.
33. Wood D. European and American recommendations for coronary heart disease prevention. Eur Heart J 1998;19 Suppl A(Suppl A):A12-19.
34. Aebi S, Davidson T, Gruber G, et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011;22(Suppl 6):vi12-24.
35. Aebi S, Davidson T, Gruber G, et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21(Suppl 5):v9-14.
36. Kataja V, Castiglione M, Group EGW. Primary breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009;20(Suppl 4):10-14.
37. Pestalozzi B, Castiglione M, Group EGW. Primary breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008;19(Suppl 2):ii7-10.
38. Senkus E, Kyriakides S, Penault-Llorca F, et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24 (Suppl 6):vi7-23.
39. Labianca R, Nordlinger B, Beretta GD, et al. Primary colon cancer: ESMO Clinical Practice Guidelines for diagnosis, adjuvant treatment and follow-up. Ann Oncol 2010;21(Suppl 5):v70-7.
40. Labianca R, Nordlinger B, Beretta GD, et al. Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24 (Suppl 6):vi64-72.
41. Schmoll HJ, Van Cutsem E, Stein A, et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol 2012;23:2479-516.
42. Van Cutsem E, Oliveira J, Group EGW. Primary colon cancer: ESMO clinical recommendations for diagnosis, adjuvant treatment and follow-up. Ann Oncol 2009;20(Suppl 4):49-50.
43. Horwich A, Hugosson J, de Reijke T, et al. Prostate cancer: ESMO Consensus Conference Guidelines 2012. Ann Oncol 2013;24:1141-62.
44. Horwich A, Parker C, Bangma C, et al. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21(Suppl 5):v129-33.
45. Dummer R, Hauschild A, Guggenheim M, et al. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23(Suppl 7):vii86-91.
46. Willemze R, Dreyling M, Group EGW. Primary cutaneous lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009;20(Suppl 4):115-18.
47. D'Addario G, Fruh M, Reck M, et al. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21(Suppl 5):v116-19.
48. Fruh M, De Ruysscher D, Popat S, et al. Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24(Suppl 6):vi99-105.
49. Colombo N, Carinelli S, Colombo A, et al. Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23(Suppl 7):vii27-32.
50. Dreyling M, Geisler C, Hermine O, et al. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up dagger. Ann Oncol 2014;25(Suppl 3):iii83-92.
51. Dreyling M, Thieblemont C, Gallamini A, et al. ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. Ann Oncol 2013;24:857-77.
52. Eichenauer DA, Engert A, Andre M, et al. Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014;25 (Suppl 3):iii70-5.
53. Ghielmini M, Vitolo U, Kimby E, et al. ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). Ann Oncol 2013;24:561-76.
54. Kerlikowske K, Grady D, Rubin SM, et al. Efficacy of screening mammography. A meta-analysis. JAMA 1995;273:149-54.
55. Martin-Hirsch P, Lilford R, Jarvis G, et al. Efficacy of cervical-smear collection devices: a systematic review and meta-analysis. Lancet 1999;354:1763-70.
56. Jellema P, van der Windt DA, Bruinvels DJ, et al. Value of symptoms and additional diagnostic tests for colorectal cancer in primary care: systematic review and meta-analysis. BMJ 2010;340:c1269.
57. Bafounta ML, Beauchet A, Aegerter P, et al. Is dermoscopy (epiluminescence microscopy) useful for the diagnosis of melanoma? Results of a meta-analysis using techniques adapted to the evaluation of diagnostic tests. Arch Dermatol 2001;137:1343-50.
58. Brenner H, Stock C, Hoffmeister M. Effect of screening sigmoidoscopy and screening colonoscopy on colorectal cancer incidence and mortality: systematic review and meta-analysis of randomised controlled trials and observational studies. BMJ 2014;348:g2467.
59. Abubakar I, Griffiths C, Ormerod P, et al. Diagnosis of active and latent tuberculosis: summary of NICE guidance. BMJ 2012;345:e6828.
60. Diagnostic Standards and Classification of Tuberculosis in Adults and Children. This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Disease Society of America, September 1999. Am J Respir Crit Care Med 2000;161:1376-95.
61. Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections-full version. Clin Microbiol Infect 2011;17(Suppl 6): E1-59.
62. Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med 2007;146:340-54.
63. Roy A, Eisenhut M, Harris RJ, et al. Effect of BCG vaccination against Mycobacterium tuberculosis infection in children: systematic review and meta-analysis. BMJ 2014;349:g4643.
64. US Food and Drug Administration website: http://www. fda.gov/Safety/MedWatch/HowToReport/ucm053087.htm
65. Mariette X, Gottenberg JE, Ravaud P, et al. Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries. Rheumatology (Oxford) 2011;50:222-9.
66. Rubin G, Meineche-Schmidt V, Roberts A, et al. The use of consensus to develop guidelines for the management of Helicobacter pylori infection in primary care. European Society for Primary Care Gastroenterology. Fam Pract 2000;17(Suppl 2):S21-6.
67. Kanis JA, McCloskey EV, Johansson H, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2013;24:23-57.
68. Hippisley-Cox J, Coupland C. Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractureScores. BMJ 2009;339:b4229.
69. Kanis JA, Johnell O, Oden A, et al. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 2008;19:385-97.
70. NCCfMHLUNIfHaCE. Depression in adults with a chronic physical health problem. Treatment and management[NICE Clinical Guidelines, no. 91]. 2009.
71. Joffres M, Jaramillo A, Dickinson J, et al, Canadian Task Force on Preventive Health C. Recommendations on screening for depression in adults. CMAJ 2013;185:775-82.
72. Force USPST. Screening for depression: recommendations and rationale. Ann Intern Med 2002;136:760-4.
73. Force USPST. Screening for depression in adults: U.S. preventive services task force recommendation statement. Ann Intern Med 2009;151:784-92.
74. Ashford NA, Bauman P, Brown HS, et al. Cancer risk: role of environment. Science 2015;347:727.
75. Steineck G, Helgesen F, Adolfsson J, et al. Quality of life after radical prostatectomy or watchful waiting. N Engl J Med 2002;347:790-6.
76. Bender Ignacio RA, Chu J, Power MC, et al. Influence of providers and nurses on completion of non-targeted HIV screening in an urgent care setting. AIDS Res Ther 2014;11:24.
77. Zangi HA, Ndosi M, Adams J, et al. EULAR recommendations for patient education for people with inflammatory arthritis. Ann Rheum Dis 2015;74:954-62.